NCT06433440View on ClinicalTrials.gov

Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

August 30, 2021

Study Completion Date

August 30, 2021

Conditions
Rabies
Interventions
BIOLOGICAL

PVRV

Group-1 will receive PVRV ID on on the following days: Day0, Day3, Day7, while group-2 will receive PVRV IM on Day0, Day3, Day7, Day14, and Day28.

Trial Locations (1)

25000

Mohammad Ismail, Peshawar

All Listed Sponsors
collaborator

Hayatabad Medical Complex

OTHER_GOV

lead

University of Peshawar

OTHER

NCT06433440 - Safety and Immunogenicity of Purified Verocell Rabies Vaccine PVRV Administered Intramuscularly and Intradermally | Biotech Hunter | Biotech Hunter